GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anatara Lifesciences Ltd (ASX:ANR) » Definitions » Buyback Yield %

Anatara Lifesciences (ASX:ANR) Buyback Yield % : -14.68 (As of May. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Anatara Lifesciences Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Anatara Lifesciences's current buyback yield was -14.68%.


Anatara Lifesciences Buyback Yield % Historical Data

The historical data trend for Anatara Lifesciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anatara Lifesciences Buyback Yield % Chart

Anatara Lifesciences Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only - - -26.19 0.13 -44.91

Anatara Lifesciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 - -66.05 -15.67 -52.63

Competitive Comparison of Anatara Lifesciences's Buyback Yield %

For the Biotechnology subindustry, Anatara Lifesciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatara Lifesciences's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Anatara Lifesciences's Buyback Yield % falls into.



Anatara Lifesciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Anatara Lifesciences's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.189 + 1.697) / 3.357777325
=-44.91%

Anatara Lifesciences's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.083 + 1.055) * 2 / 3.693668
=-52.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.


Anatara Lifesciences Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Anatara Lifesciences's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anatara Lifesciences (ASX:ANR) Business Description

Traded in Other Exchanges
N/A
Address
c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.

Anatara Lifesciences (ASX:ANR) Headlines

No Headlines